IQVIA (NYSE:IQV) Reaches New 1-Year High – Time to Buy?

IQVIA Holdings Inc. (NYSE:IQV)’s stock price reached a new 52-week high on Wednesday . The company traded as high as $266.08 and last traded at $265.7970, with a volume of 567514 shares. The stock had previously closed at $258.35.

Analyst Upgrades and Downgrades

IQV has been the topic of several recent research reports. HSBC reaffirmed a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Stifel Nicolaus boosted their price objective on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a report on Saturday. Robert W. Baird lifted their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. upped their price objective on IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $241.88.

IQVIA Stock Up 2.4%

The company has a market cap of $43.56 billion, a price-to-earnings ratio of 32.91, a PEG ratio of 2.23 and a beta of 1.18. The business has a fifty day moving average of $225.75 and a two-hundred day moving average of $190.73. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has approved a stock repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This trade represents a 15.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 12,913 shares of company stock valued at $3,098,793. Insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently made changes to their positions in IQV. Financial Freedom LLC purchased a new position in IQVIA in the first quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new position in shares of IQVIA during the 1st quarter worth $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA during the 4th quarter worth about $27,000. Compass Financial Management LLC purchased a new stake in IQVIA in the 2nd quarter valued at about $27,000. Finally, Gilpin Wealth Management LLC acquired a new position in IQVIA in the fourth quarter valued at about $27,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.